Image via discovered:computerworld.com.au
Last updated
Automation Anywhere: Partnership
Strategic partnerships with Cisco, Nvidia, Okta, and OpenAI for EnterpriseClaw platform development and integration
Source: discovered:computerworld.com.au
The leadership read
Alliances like this can broaden sales commercial leadership bench strength.
Market context: This lands while the Talent Market Index reads 111.1 (Hot) — up 5.2 versus the prior month — and EMEA signal share is easing (-4.4pts).
Automation Anywhere: 2 signals in the last 90 days — above the Sales median of 1 across 25 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 43 days.
MitchelLake in this thematic
From the MitchelLake archive
Also at Automation Anywhere →
More signals across Sales
Partnership · EMEA
Trustpilot →Trustpilot integrated customer review functionality into Shopify stores, expanding distribution and embedded review capabilities.
Partnership · EMEA
NICE Actimize →NICE Actimize won a major mandate with DNB Bank ASA (Norway's largest financial services group) to deploy X-Sight Enterprise platform for fraud and financial crime detection. Infosys selected as systems integration partner for end-to-end modernization.
Partnership · EMEA
Napier AI →Napier AI partnered with Concentrix to expand its Continuum compliance platform into ANZ markets, leveraging Concentrix's scale and transformation expertise to serve financial services organizations.
Ma Activity · EMEA
Datadog →Datadog acquired Adaptive ML to accelerate AI R&D capabilities. The acquisition will integrate Adaptive ML into Datadog's AI lab to build frontier AI infrastructure for observability and security research.
Capital Raising · EMEA
Liftoff Mobile →Liftoff Mobile completed IPO on Nasdaq, raising $437 million. CEO Jeremy Bondy led the company public after market stabilization, achieving tenth consecutive quarter of growth. Backed by Blackstone private equity.
Product Launch · EMEA
Novo Nordisk →Novo Nordisk's investigational zenagamtide (once-weekly GLP-1 receptor agonist) demonstrated significant A1C reductions and up to 14.6% weight loss in Phase 2 study of adults with type 2 diabetes, presented at ADA 2026
Intelligence powered by Autonodal ↗